Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions.

Raus S, Coin S, MonsurrĂ² V.

Korean J Hematol. 2011 Dec;46(4):229-38. doi: 10.5045/kjh.2011.46.4.229. Epub 2011 Dec 27.

2.

Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.

Liikanen I, MonsurrĂ² V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A.

Mol Ther. 2011 Oct;19(10):1858-66. doi: 10.1038/mt.2011.144. Epub 2011 Jul 26.

3.

Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II.

Zhang H, Niu B, Hu JF, Ge S, Wang H, Li T, Ling J, Steelman BN, Qian G, Hoffman AR.

J Cell Biol. 2011 May 2;193(3):475-87. doi: 10.1083/jcb.201101021.

4.

Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.

Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD, Yang DQ, Li HL, Ding M, Wei N, Zhang KJ, Xu B, Liu XR, Qian QJ, Liu XY.

Gene Ther. 2011 Aug;18(8):765-77. doi: 10.1038/gt.2011.16. Epub 2011 Mar 17.

PMID:
21412282
5.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.

Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.

6.

Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts.

Wang H, Song X, Zhang H, Zhang J, Shen X, Zhou Y, Fan X, Dai L, Qian G, Hoffman AR, Hu JF, Ge S.

Int J Cancer. 2012 Jan 15;130(2):443-53. doi: 10.1002/ijc.26013. Epub 2011 May 30.

7.

Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.

Pesonen S, Kangasniemi L, Hemminki A.

Mol Pharm. 2011 Feb 7;8(1):12-28. doi: 10.1021/mp100219n. Epub 2010 Dec 22. Review.

PMID:
21126047
8.

Oncolytic virotherapy reaches adolescence.

Hammill AM, Conner J, Cripe TP.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1253-63. doi: 10.1002/pbc.22724. Epub 2010 Aug 23. Review.

PMID:
20734404
9.

Targeted tumor gene therapy based on loss of IGF2 imprinting.

Pan Y, He B, Li T, Zhu C, Zhang L, Wang B, Xu Y, Qu L, Hoffman AR, Wang S, Hu J.

Cancer Biol Ther. 2010 Aug 1;10(3):290-8. Epub 2010 Aug 21.

10.

Paramyxovirus entry and targeted vectors for cancer therapy.

Cattaneo R.

PLoS Pathog. 2010 Jun 24;6(6):e1000973. doi: 10.1371/journal.ppat.1000973. No abstract available.

11.

CTCF: master weaver of the genome.

Phillips JE, Corces VG.

Cell. 2009 Jun 26;137(7):1194-211. doi: 10.1016/j.cell.2009.06.001. Review.

12.

Adenoviral E1A function through Myc.

Chakraborty AA, Tansey WP.

Cancer Res. 2009 Jan 1;69(1):6-9. doi: 10.1158/0008-5472.CAN-08-3026. Review.

13.

Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

Zhang H, Wang H, Zhang J, Qian G, Niu B, Fan X, Lu J, Hoffman AR, Hu JF, Ge S.

Mol Ther. 2009 Jan;17(1):57-64. doi: 10.1038/mt.2008.236. Epub 2008 Nov 18.

14.

CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop.

Li T, Hu JF, Qiu X, Ling J, Chen H, Wang S, Hou A, Vu TH, Hoffman AR.

Mol Cell Biol. 2008 Oct;28(20):6473-82. doi: 10.1128/MCB.00204-08. Epub 2008 Jul 28.

15.

The current status of adenovirus-based cancer gene therapy.

Shirakawa T.

Mol Cells. 2008 Jun 30;25(4):462-6. Epub 2008 May 6. Review.

16.

Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming.

Chen HL, Li T, Qiu XW, Wu J, Ling JQ, Sun ZH, Wang W, Chen W, Hou A, Vu TH, Hoffman AR, Hu JF.

EMBO J. 2006 Nov 15;25(22):5329-38. Epub 2006 Nov 2.

17.

CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1.

Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW, Cherry AM, Hoffman AR.

Science. 2006 Apr 14;312(5771):269-72.

18.

The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression.

Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, Elledge SJ, Gallimore PH.

Nature. 2005 Dec 1;438(7068):690-5.

PMID:
16319895
19.

Viral vectors for cancer gene therapy: viral dissemination and tumor targeting.

Jia W, Zhou Q.

Curr Gene Ther. 2005 Feb;5(1):133-42. Review.

PMID:
15638717
20.

Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis.

Takeuchi A, Mishina Y, Miyaishi O, Kojima E, Hasegawa T, Isobe K.

Nat Genet. 2003 Feb;33(2):172-6. Epub 2003 Jan 13.

PMID:
12524542

Supplemental Content

Support Center